Industry-Sponsored Research Week
Industry-Sponsored Research Management sample issue

Extension to UK drug discovery alliance announced

By David Schwartz
Published: September 5th, 2017

A strategic drug discovery alliance between Cancer Research UK, Newcastle University and Astex Pharmaceuticals has been extended for another three years.

The five-year-old alliance has involved multiple projects in target validation and early-stage medicinal chemistry, with some progressing towards the more advanced preclinical stages.

 “We’re delighted to extend this major collaboration, which accelerates the development of Cancer Research UK’s world class work into new treatments for patients,” said Dr Iain Foulkes, non-profit research organization’s executive director of research and innovation. “Promising new compounds resulting from this partnership are now progressing towards the next stage of development. Multi-project alliances like this are powerful engines for innovation and drug discovery, and this announcement underlines Cancer Research UK’s exceptional track record of bringing these together successfully.”

 “The innovative academic-industry collaborative model pioneered with Astex has been a genuine success and we are thrilled to be able to continue working in partnership on our drug discovery research,” added Steve Wedge, professor of Stratified Cancer Medicine Discovery at Newcastle University. “The alliance benefits significantly from complementary expertise and provides a route to progress promising novel therapies towards clinical use.”

 “The extension of our agreement with Newcastle and Cancer Research UK underlines the success of our existing alliance and the importance we place on collaboration with world leading academic research groups to strengthen our efforts to discover new treatments for patients,” added Dr Harren Jhoti, Astex president and CEO.

Under the terms of the agreement, researchers based at Newcastle will work towards the identification and development of new cancer drugs and associated biomarkers. Astex will retain the right to an exclusive worldwide license for the most promising projects, and Cancer Research UK and Newcastle University will be eligible to receive milestone and royalty payments when compounds are successfully commercialized. The new agreement also provides for a further extension at the end of the three-years.

Source: EPM

Posted under: Industry-Sponsored Research Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment